Supercharged immune cells take on melanoma after standard treatments fail

NCT ID NCT05629546

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This early-phase study tests whether specially trained natural killer (NK) cells, given with two immunotherapy drugs (nivolumab and relatlimab), are safe and can shrink tumors in people with advanced melanoma that stopped responding to standard checkpoint inhibitors. About 33 adults will receive NK cells from either their own blood or a donor. The goal is to find a new option for patients who have run out of effective treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.